Related Experiment Video

Updated: May 20, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Inhibition of renin and the (pro)renin receptor system

Cuie Guang1, Bo Jiang, Robert D Phillips

  • 1State Key Laboratory of Food Science and Technology, Jiangnan University , 1800 Lihu Avenue, Wuxi, Jiangsu 214122, China. guang1226@hotmail.com

Blood Pressure
|July 11, 2012
PubMed

Insights

This review explores inhibiting renin and the (pro)renin receptor [(P)RR] system to combat hypertension and cardiovascular diseases (CVDs). It covers pharmacological and nutritional strategies targeting the renin-angiotensin system (RAS).

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Pharmacology

Background:

  • The renin-angiotensin system (RAS) plays a critical role in regulating blood pressure.
  • Overactivation of the renin-angiotensin-converting enzyme (ACE)-angiotensin (Ang) II-Ang II type 1 receptor (AT(1)R) axis is linked to hypertension and cardiovascular diseases (CVDs).
  • Renin is the rate-limiting enzyme in this cascade, and its activity, along with the (pro)renin receptor [(P)RR], contributes to profibrotic gene expression.

Purpose of the Study:

  • To review the mechanisms by which renin and the (P)RR system contribute to cardiovascular pathology.
  • To discuss current and potential therapeutic strategies for inhibiting renin and the (P)RR system.
  • To explore both pharmacological and nutritional approaches for managing hypertension and CVDs by targeting these pathways.

Main Methods:

  • Literature review of studies on the renin-angiotensin system (RAS) and (pro)renin receptor [(P)RR].
  • Analysis of research on pharmacological inhibitors of renin and (P)RR.
  • Examination of nutritional factors influencing RAS and (P)RR activity.

Main Results:

  • Renin and (P)RR activation exacerbate hypertension and cardiovascular diseases (CVDs).
  • Inhibition of renin and (P)RR shows potential in managing these conditions.
  • Both pharmacological agents and nutritional interventions can modulate the RAS and (P)RR system.

Conclusions:

  • Targeting renin and the (P)RR system offers a promising therapeutic avenue for hypertension and cardiovascular diseases (CVDs).
  • A dual approach combining pharmacological and nutritional strategies may provide comprehensive management.
  • Further research is warranted to optimize these interventions for clinical application.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...